Clover Corporation Limited · ASX:CLV

Clover — Citi's 9th Annual Australian and New Zealand Investment Conference 2017

16 slides from Clover's conference presentation, Oct 18, 2017

  1. Slide 1: Citi's 9th Annual Australian and New Zealand Investment Conference

    Citi’s 9th Annual Australian and New Zealand Investment Conference Clover Corporation Presentation Peter Davey- Managing Dircetor & CEO 17 & 18 October 2017

  2. Slide 2: Vision and Mission Statement

    Vision and Mission Statement Vision To optimise the health and development of adults, infants and children. Mission To deliver science based bioactives which provide health benefits to the adults, infants, children and medical food markets. 2

  3. Slide 3: Full Year Performance Highlights

    Full Year Performance Highlights Total Revenue New products released to $47.9m up 12% develop additional market segments in Sports driven by improved Nutrition demand; highest ever recorded revenue Inventory at $18.8m Net Profit $3.6m up up 33% on prior year to meet increased demand 64% on 2016

  4. Slide 4: Clover's Value Chain

    Clover’s Value Chain Omega 3 – EPA / DHA Omega 6 - ARA Product source Fish Single Cell Other Marine Crude processors Market Participants Refiners Clover primarily operates in this sector of the supply chain Encapsulation Sales and distribution Applications / Markets Dietary Food and Clinical Pharmac

  5. Slide 5: Encapsulation Technology

    48% Oil Encapsulation Technology 52% Encapsulant  Patented Microencapsulation Technology with best in class application performance: D201.010 Driphorm HiDHA 50 ‒ Protection against oxidation and provides superior sensory stability ‒ Suitable for a wide range of food applications ‒ Benefits of non-r

  6. Slide 6: Market Update

    Market Update Market changes Outcomes for Clover  New Chinese infant formula regulations  Regulated Chinese infant formula industry, requiring manufacturers to hold a CFDA increased quality controls positions Clover license by January 2018 as a premium supplier. Many of Clover’s  New EU regulatio

  7. Slide 7: Full Year Results 2017

    Full Year Results 2017 7

  8. Slide 8: Full Year 2017 Results

    Full Year 2017 Results AUD million 4E Reported 4E Reported  11.5% year on year revenue 31 Jul 2017 31 Jul 2016 growth Revenue $47.9 $42.9  Increased sales across all EBITDA $6.1 $3.3 markets EBIT $5.5 $2.8  EBIT $5.5m (PY $2.8m) NPBT $5.0 $3.1  NPBT of $5.0m includes Tax ($1.4) ($0.9) ~$0.5m unr

  9. Slide 9: Balance Sheet July 2017

    Balance Sheet 31 July 2017 AUD million Reported Reported Movement 31 July 2017 31 July 2016  Cash balance strong $5.9m Cash $5.9 $8.2 2.3  Trade $12.1 $10.9 1.2   Trade receivables Receivables reflect the Inventories $18.8 $13.6 5.2  increased sales activity Total Current $37.6 $33.1 4.5  Asse

  10. Slide 10: Sales by Geography & Product

    Sales by Geography & Product  Sales across all regions  Encapsulated Tuna oil have grown during 2017 leads sales revenue with encapsulated Algal oils and  European and American other oils represented in markets provide new other products opportunities FY 2017 Geographic FY 2017 Product Americas E

  11. Slide 11: An Update on Growth Platforms

    An Update on Growth Platforms Infant Market formula Development customers Product Development 11

  12. Slide 12: Growth Platform: Infant formula

    Growth Platform Market Infant formula Development customer s Infant formula provides further growth Product Development  The Chinese regulators changed rulings during 2017. Initially they proposed banning ‘grey imports’ (called CBEC) closing the channel to market for many infant formula brands, and

  13. Slide 13: Growth Platform: Product Development

    Market Infant formula Development customers Growth Platform Product Development Products for new segments  Clover’s Hypoallergenic DHA product is now being purchased and used in infant formula applications  A new highly concentrated DHA product which delivers 60% oil in a powder form is on trial w

  14. Slide 14: Growth Platform: New markets development

    Growth Platform Market Development Infant formula customers New markets development Product Development  Clover has aligned with distributors across the USA, Europe & Asia, providing market access and the capability to service new customer opportunities  To generate a presence in the market and ac

  15. Slide 15: FY2018 Outlook & Priorities

    FY2018 Outlook & Priorities  Further market development through a specialised distribution network  Product development enhancing our capability to fortify foods, drinks and other products with Omega 3  Growth into new markets of India and the Middle East  Research & Development in collaboration

  16. Slide 16: Disclaimer

    Disclaimer The release, publication or distribution of this presentation in certain jurisdictions may be restricted by law and therefore persons in such jurisdictions into which this presentation is released, published or distributed should inform themselves about and observe such restrictions. This

Clover — Citi's 9th Annual Australian and New Zealand Investment Conference 2017 on 6ix